Also Read: Corcept Therapeutics’ Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast CATALYST is a prospective Phase 4 study with two parts.

Korlym showed a 1.47% reduction in hemoglobin A1c in patients with hypercortisolism and type 2 diabetes, surpassing placebo's 0.15%. CATALYST Phase 4 study screened 1,057 patients, confirming ...

The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past ...

The study found that the drug Korlym significantly improved blood sugar levels in affected patients. According to InvestingPro analysis, the company appears to be trading above its Fair Value, though ...

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%. The company’s sole-marketed drug, Korlym (mifepristone ...

The study found that the drug Korlym significantly improved blood sugar levels in affected patients. According to InvestingPro analysis, the company appears to be trading above its Fair Value ...

Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind ...

On Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym ...

Corcept Therapeutics (CORT) announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym in patients with ...